Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-isopropyl-5-(2-phenylethenyl)benzene-1,3-diol
2. 3,5-dh4is
3. 5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol
4. Benvitimod
5. Gsk2894512
6. Tapinarof
7. Wbi-1001
1. Benvitimod
2. Tapinarof
3. 79338-84-4
4. Wbi-1001
5. Gsk2894512
6. Vtama
7. Wbi 1001
8. Tapinarof [usan]
9. 3,5-dihydroxy-4-isopropyl-trans-stilbene
10. (e)-2-(1-methylethyl)-5-(2-phenylethenyl)-1,3-benzenediol
11. 2-isopropyl-5-styrylbenzene-1,3-diol
12. Gsk-2894512
13. 5-[(e)-2-phenylethenyl]-2-propan-2-ylbenzene-1,3-diol
14. (e)-2-isopropyl-5-styrylbenzene-1,3-diol
15. 84hw7d0v04
16. Tapinarof (usan)
17. 1,3-benzenediol, 2-(1-methylethyl)-5-[(1e)-2-phenylethenyl]-
18. 115781-08-3
19. 1,3-benzenediol, 2-(1-methylethyl)-5-(2-phenylethenyl)-, (e)-
20. 3,5-dh4is
21. Unii-84hw7d0v04
22. 1,3-benzenediol, 2-(1-methylethyl)-5-((1e)-2-phenylethenyl)-
23. Benvitimod (tapinarof)
24. Tapinarof [inn]
25. Tapinarof [who-dd]
26. Schembl918343
27. Chembl259571
28. Gtpl9686
29. Dtxsid301045262
30. Bcp13569
31. Ex-a4877
32. Zinc5761533
33. (e)-4-isopropylstilbene-3,5-diol
34. Mfcd13193203
35. S9700
36. Akos025296109
37. Db06083
38. Wb-1001
39. Ac-36567
40. As-44364
41. Hy-109044
42. Cs-0031487
43. D11365
44. A914284
45. Q4634086
46. 2-(1-methylethyl)-5-[(e)-2-phenylethenyl]benzene-1,3-diol
47. 2-(1-methylethyl)-5-((1e)-2-phenylethenyl)-1,3-benzenediol
48. 5-((1e)-2-phenylethen-1-yl)-2-(propan-2-yl)benzene-1,3-diol
| Molecular Weight | 254.32 g/mol |
|---|---|
| Molecular Formula | C17H18O2 |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 254.130679813 g/mol |
| Monoisotopic Mass | 254.130679813 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 280 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in psoriasis and psoriatic disorders.
WBI-1001 selectively modulates the cytokine cascade deep under the skin, a process that rapidly decreases inflammations and skin plague. It targets the four major mechanisms involved in the disease.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 58175-0646
Start Marketing Date : 2022-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50379-0026
Start Marketing Date : 2023-08-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Organon
Deal Size: $1,200.0 million Upfront Cash: $175.0 million
Deal Type: Acquisition October 28, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Organon
Deal Size : $1,200.0 million
Deal Type : Acquisition
Organon Acquires Dermavant's VTAMA® Cream for Dermatology
Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : $175.0 million
October 28, 2024
Details:
Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Organon
Deal Size: $1,200.0 million Upfront Cash: $175.0 million
Deal Type: Acquisition September 18, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Organon
Deal Size : $1,200.0 million
Deal Type : Acquisition
Organon Pays up to $1.2B to Acquire Dermavant and its Steroid-Free Skin Cream Vtama
Details : Through the acquisition, Organon will leverage the Dermavant pipeline, which includes Vtama (tapinarof) cream. It is indicated for the treatment of f plaque psoriasis in adults.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : $175.0 million
September 18, 2024
Details:
Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of psoriasis in adults and atopic dermatitis in adults & children 2 years of age & above.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
Details : Vtama (tapinarof) cream is an aryl hydrocarbon receptor agonist steroid-free, topical cream, for the treatment of psoriasis in adults and atopic dermatitis in adults & children 2 years of age & above.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist for once-daily topical treatment of atopic dermatitis in patients 2 years and older.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Announces FDA Acceptance Of sNDA for VTAMA® Cream
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist for once-daily topical treatment of atopic dermatitis in patients 2 years and older.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 29, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, developed as a once-daily, steroid-free topical cream for atopic dermatitis in adults and children 2 years and older.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Submits sNDA for VTAMA® Cream, 1% for Atopic Dermatitis
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, developed as a once-daily, steroid-free topical cream for atopic dermatitis in adults and children 2 years and older.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Details:
Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, in phase 3 trials as a once-daily, steroid-free topical cream for Atopic Dermatitis.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Reports Positive Data from ADORING Program with VTAMA® Cream
Details : Vtama (tapinarof) cream is a novel aryl hydrocarbon receptor agonist, in phase 3 trials as a once-daily, steroid-free topical cream for Atopic Dermatitis.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 11, 2024
Details:
Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1...
Details : Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 06, 2023
Details:
Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for moderate to severe atopic dermatitis in adults and children as young as two years old.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for moderate to severe atopic dermatitis in adults and children as young as two years old.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2023
Details:
Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2023
Details:
Vtama (tapinarof) is an aryl hydrocarbon receptor (AhR) agonist. It is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Brand Name: Vtama
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA® (tapinarof) Cream, 1% for...
Details : Vtama (tapinarof) is an aryl hydrocarbon receptor (AhR) agonist. It is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.
Brand Name : Vtama
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Brand Name : VTAMA
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%
Packaging :
Approval Date : 2022-05-23
Application Number : 215272
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2036-05-19
US Patent Number : 11458108
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2036-05-19
US Patent Number : 11622945
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2036-05-19
US Patent Number : 10195160
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2038-11-13
US Patent Number : 11597692
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-11-13
Patent Expiration Date : 2036-05-19
US Patent Number : 11617724
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2038-11-13
US Patent Number : 10647649
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 215272
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-11-13
Patent Expiration Date : 2036-05-19
US Patent Number : 10426743
Drug Substance Claim :
Drug Product Claim :
Application Number : 215272
Patent Use Code : U-2625
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2036-05-19
US Patent Number : 11612573
Drug Substance Claim :
Drug Product Claim :
Application Number : 215272
Patent Use Code : U-2625
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-05-19
Patent Expiration Date : 2039-11-13
US Patent Number : 11590088
Drug Substance Claim :
Drug Product Claim :
Application Number : 215272
Patent Use Code : U-2625
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-11-13
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]US Exclusivities
Exclusivity Code : NCE
Exclusivity Expiration Date : 2027-05-23
Application Number : 215272
Product Number : 1
Exclusivity Details :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
